News - Santarus

Filter

Current filters:

Santarus

Popular Filters

US FDA accepts Ruconest filing from Santarus and Pharming

18-06-2013

US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

Pharming and Santarus file BLA for Ruconest with US FDA

18-04-2013

Netherlands-based Pharming Group (NYSE Euronext: PHARM) and US licensee Santarus (Nasdaq: SNTS) have…

North AmericaPharmaceuticalPharmingRare diseasesRegulationRuconestSantarus

Pharming gets $10 million milestone from Santarus on Ruconest progress

26-11-2012

Loss-making Dutch biotech company Pharming Group NV (NYSE Euronext: PHARM) said yesterday that, following…

BiotechnologyFinancialPharmingRare diseasesResearchRuconestSantarus

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

06-09-2012

US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Santarus and Depomed expand US deal on Glumetza

23-08-2011

US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Back to top